Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of mineralocorticoid receptor inhibition on endothelial function in metabolic syndrome
2010-018639-17Phase 3Completed
- Sponsor
- University Hospital Erlangen
- Start
- Mar 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of eplerenone in cardiometabolic risk (CMR), sponsored by University Hospital Erlangen. Primary endpoint: Change in basal nitric oxide activity. Started Mar 2010; status: completed.
02
Drugs
eplerenone
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2010-018639-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018639-17.